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Abstract 
 
It is known since the 1950s that enhancement of the levels of the monoamines dopamine (DA), 
serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE) in the brain will relieve the 
symptoms of major depression, and current therapies are still based on this mechanism. However, 
all available antidepressants today are still suffering from slow onset of therapeutic action, as well 
as adverse effects and lack of efficacy. Therefore, development of compounds with new 
mechanisms of action for treatment of depression is needed. 
One of the most important stages of the drug discovery process is the generation of lead 
compounds. Structure-activity relationships (SARs) are well integrated in modern drug discovery 
and have been used in the process of developing new leads. The tetrahydropyridine/piperidine 
indoles are known to affect multiple targets of the dopaminergic and serotonergic systems in the 
brain. This class of indoles can easily be modified and they possess the necessary properties for a 
lead, such as low molecular weight and high water solubility. This thesis is focused on further 
exploring the SAR around tetrahydropyridine/piperidine indoles by introduction of substituents 
and/or bioisosteric replacements of the indole core with the aim of developing novel compounds 
acting at the dopaminergic and serotonergic systems in the brain. By using in vivo and in vitro 
screening approaches, 5-HT type 6 receptor (5-HT6) agonists, DA type 2 receptor (DA D2) 
antagonists, 5-HT reuptake transporters (SERT) inhibitors, dual DA D2 antagonists/SERT inhibitors 
and finally reversible monoamine oxidase A (MAO A) inhibitors were identified after modifications 
of the chemical lead. In addition, the SAR of 6-substituted 3-(pyrrolidin-1-ylmethyl)chromen-2-
ones (coumarin derivatives) were also investigated and were identified as selective and reversible 
MAO A inhibitors. 
Three compounds, i.e. the 5-HT6 agonist 81, the dual DA D2 antagonist/SERT inhibitor 158 
and the MAO A inhibitor 134 have been identified to be of potential interest as novel 
antidepressants. 
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